Propanc Biopharma, Inc.: Form 10-Q/A for the period ended Dec 31, 2011
Filed with the SEC on Mar 7, 2012 and accepted by EDGAR at Mar 7, 2012, 17:28 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2011-10-01 to 2011-12-31 | $0 | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2011-07-01 to 2011-12-31 | $5.3k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2011-10-01 to 2011-12-31 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2011-07-01 to 2011-12-31 | −$6.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2011-10-01 to 2011-12-31 | $614 | us-gaap:InterestExpense |
| Interest expense | 6 months2011-07-01 to 2011-12-31 | $797 | us-gaap:InterestExpense |
| Income tax | 3 months2011-10-01 to 2011-12-31 | −$170.5k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2011-07-01 to 2011-12-31 | −$173.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2011-10-01 to 2011-12-31 | −$2.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2011-07-01 to 2011-12-31 | −$5.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2011-10-01 to 2011-12-31 | −$0.03 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2011-07-01 to 2011-12-31 | −$0.09 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2011-07-01 to 2011-12-31 | −$40.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2011-07-01 to 2011-12-31 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2011-12-31 | $4.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2011-12-31 | $4.9m | us-gaap:Assets |
| Current liabilities | At period end2011-12-31 | $354.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2011-12-31 | $354.3k | us-gaap:Liabilities |
| Shareholders' equity | At period end2011-12-31 | $4.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001354488-12-001037. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.